280 related articles for article (PubMed ID: 34321401)
1. Role of Hypertension on the Severity of COVID-19: A Review.
Peng M; He J; Xue Y; Yang X; Liu S; Gong Z
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e648-e655. PubMed ID: 34321401
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
3. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
4. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
5. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
6. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
7. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
Tadic M; Cuspidi C
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
[No Abstract] [Full Text] [Related]
8. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
9. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
12. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Edmonston DL; South AM; Sparks MA; Cohen JB
Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
[TBL] [Abstract][Full Text] [Related]
14. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.
Shah H; Khan MSH; Dhurandhar NV; Hegde V
Acta Diabetol; 2021 Jul; 58(7):831-843. PubMed ID: 33587177
[TBL] [Abstract][Full Text] [Related]
15. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
18. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.
Kario K; Morisawa Y; Sukonthasarn A; Turana Y; Chia YC; Park S; Wang TD; Chen CH; Tay JC; Li Y; Wang JG;
J Clin Hypertens (Greenwich); 2020 Jul; 22(7):1109-1119. PubMed ID: 32643874
[TBL] [Abstract][Full Text] [Related]
20. Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.
Zlacká J; Stebelová K; Zeman M; Herichová I
Physiol Res; 2021 Dec; 70(S2):S177-S194. PubMed ID: 34913351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
